344331-90-4

Usage

Uses

Used in Agricultural Industry:
(6-BROMO-2-PYRIDINYL)-CARBAMIC ACID,1,1-DIMETHYLETHYL ESTER is used as a herbicidal agent for controlling a variety of broadleaf and grassy weeds. It is applied to inhibit the enzyme acetolactate synthase, essential for the biosynthesis of branched-chain amino acids, which in turn leads to the death of the targeted weeds, ensuring the healthy growth of crops and reducing weed competition.

InChI:InChI=1/C10H13BrN2O2/c1-10(2,3)15-9(14)13-8-6-4-5-7(11)12-8/h4-6H,1-3H3,(H,12,13,14)

Upstream product

• 21190-87-4 6-bromo-pyridine-2-carboxylic acid 
• 75-65-0 tert-butyl alcohol 
• 19798-81-3 2-Amino-6-bromopyridine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 870703-61-0 di-tert-butyl (6-bromo-2-pyridinyl)imidodicarbonate 
• 75-44-5 phosgene 
• 34619-03-9 tert-butyldicarbonate 

Downstream Products

• 19798-81-3 2-Amino-6-bromopyridine 
• 762275-81-0 {6-[4-(tert-butyl-dimethyl-silanyloxymethyl)-5-ethyl-2-methoxy-phenyl]-pyridin-2-yl}-carbamic acid tert-butyl ester 
• 762275-83-2 (6-{4-[2-(tert-butyl-dimethyl-silanyloxy)-ethyl]-2,5-dimethoxy-phenyl}-pyridin-2-yl)-carbamic acid tert-butyl ester 
• 762275-86-5 (6-{4-[2-(tert-butyl-dimethyl-silanyloxy)-ethyl]-5-ethyl-2-methoxy-phenyl}-pyridin-2-yl)-carbamic acid tert-butyl ester 
• 959991-96-9 benzyl 4-({6-[(tert-butoxycarbonyl)amino]pyridin-2-yl}methyl)piperidine-1-carboxylate 
• 959992-02-0 tert-butyl (6-{[1-(diphenylmethyl)azetidin-3-yl]methyl}pyridin-2-yl)methylcarbamate 
• 762275-85-4 {6-[2,5-dimethoxy-4-(2-oxo-ethyl)-phenyl]-pyridin-2-yl}-carbamic acid tert-butyl ester 
• 762275-88-7 {6-[5-ethyl-2-methoxy-4-(2-oxo-ethyl)-phenyl]-pyridin-2-yl}-carbamic acid tert-butyl ester 
• 762275-89-8 {6-[4-(2-dimethylamino-ethyl)-2,5-dimethoxy-phenyl]-pyridin-2-yl}-carbamic acid tert-butyl ester 
• 762275-84-3 {6-[4-(2-hydroxy-ethyl)-2,5-dimethoxy-phenyl]-pyridin-2-yl}-carbamic acid tert-butyl ester 
• 762275-87-6 {6-[5-ethyl-4-(2-hydroxy-ethyl)-2-methoxy-phenyl]-pyridin-2-yl}-carbamic acid tert-butyl ester 
• 762275-90-1 {6-[4-(2-dimethylamino-ethyl)-5-ethyl-2-methoxy-phenyl]-pyridin-2-yl}-carbamic acid tert-butyl ester 
• 936727-83-2 (R)-(6-{4-[2-(tert-butyl-dimethyl-silanyloxymethyl)-pyrrolidine-1-sulfonyl]phenyl}pyridin-2-yl)carbamic acid tert-butyl ester 
• 936727-91-2 tert-butyl 6-(4-(N-methylsulfamoyl)phenyl)pyridin-2-ylcarbamate 

Relevant academic research and scientific papers

SUBSTITUTED PYRROLOPYRIDINES AS JAK INHIBITORS

The present invention relates to new pyrrolopyridine compounds having the structures of Formula (I)-(IV), wherein the R groups, A, B, C, D and n are as defined in the detailed description, and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibition of JAK kinase activity in a human or animal subject are also provided for the treatment diseases such as pruritus, alopecia, androgenetic alopecia, alopecia areata, vitiligo and psoriasis.

PROCESSES FOR THE PREPARATION OF FILGOTINIB

The present invention relates to processes for the preparation of Filgotinib. The present invention relates to novel processes for the preparation of filgotinib. The present invention also relates to novel intermediates for the preparation of filgotinib.

THERAPEUTIC COMPOUNDS AND USES THEREOF

The present invention relates to compounds of formula (I) and formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R5-R6 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II), or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.

PROCESS FOR PREPARATION OF t-BUTOXYCARBONYLAMINE COMPOUNDS

Provided is a process for the preparation of t-butoxycarbonylamine compounds, which comprises using phosgene or a phosgene equivalent, t-butanol, and an organic base. Even when applied to a primary or secondary amine compound having low nucleophilicity, the process enables highly selective preparation of a t-butoxycarbonylamine compound at a low cost. In the process, a t-butoxycarbonylamine compound is prepared using: phosgene or a phosgene equivalent; t-butanol; an organic base; and either a primary or secondary amine compound or a primary or secondary ammonium salt.

PYRIDINE BIARYL AMINE COMPOUNDS AND THEIR USES

The present invention provides a compound of formula (I): and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. These compounds inhibit the activity of CDK9 and are thus useful as pharmaceuticals. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds of Formula I and isomers thereof, and pharmaceutical compositions comprising such compounds.

PYRIMIDINE BIARYL AMINE COMPOUNDS AND THEIR USES

The present invention provides a pyrimidine compound of formula (I): wherein one of X and Y but not both is N, and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tantomers, diastereomers, deuterated versions, or racemates thereof. These compounds inhibit the activity of CDK9 and are thus useful as pharmaceuticals. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds of Formula I and isomers thereof, and pharmaceutical compositions comprising such compounds

N-ACYL PYRIDINE BIARYL COMPOUNDS AND THEIR USES

The present invention provides a compound of general formula:wherein Z2-Z6 include one or two nitrogen atoms as described herein, including pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. These compounds inhibit the activity of CDK9 and are thus useful as pharmaceuticals. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds of Formula I and isomers thereof, and pharmaceutical compositions comprising such compounds.

N-ACYL PYRIMIDINE BIARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS

The present invention provides a compound of the general formula (1): wherein one of X and Y is N and the other is an optionally substituted carbon atom, and Z2-Z5 represent one or two nitrogen atoms, as further described herein, including pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. These compounds inhibit the activity of CDK9 and are thus useful as pharmaceuticals and as components of pharmaceutical compositions. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds described herein or pharmaceutical compositions comprising such compounds.

2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases

The present invention relates to 2,6-diaminopyridine compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein and of diseases or conditions associated with amyloid-like proteins. The compoun

Heteroaryl Compounds and Their Uses

The present invention provides a compound of formula (I): and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. Also provided is a method of treating a disease or condition mediated by CDK9.